Organic Process Research & Development 1999, 3, 135−138
Technical Notes
Improved Stereoselective Synthesis of the â-Anomer of
1-[3,5-Bis-O-(p-chlorobenzoyl)-2-deoxy-D-ribofuranosyl]-5-iodo-2-pyrimidinone
Ralph Schure, Aye Aye Mar, Brian Pease, Wyeth Jones, Barb Felt, and Mani S. Iyer*
MediChem Research, Inc., 12305 South New AVenue, Lemont, Illinois 60439
Abstract:
this method seems to lack stereochemical control in forming
the â-anomer. Since there are no methods of epimerization11
nor any existing methods12 to synthesize the â-anomer of
1-[3,5-bis-O-(p-chlorobenzoyl)-2-deoxy-D-ribofuranosyl]-5-
iodo-2-pyrimidinone (IPdR, 3) in large scale, we were forced
to reinvestigate conditions which would give a predominantly
â-anomer.
The lack of stereochemical control has been a major hurdle in
synthesizing â-nucleosides in large scale. This paper reports a
study of the effects of different catalysts used in the synthesis
of â-nucleosides. The effects of time and temperature on r- and
â-anomers are illustrated in this paper. The yield and selectivity
of the â-nucleoside have been improved vastly at temperatures
between -30 and -40 °C and by using SnCl4 as the catalyst.
Results and Discussion
In an attempt to find a procedure that increases the â
content of the coupled reaction of 1 with the silylated
2-hydroxy-5-iodopyrimidine, the effects of three acid cata-
lysts were examined. The catalysts were p-nitrophenol,7
trimethylsilyltrifluoromethane sulfonate (trimethylsilyl tri-
flate),5 and stannic chloride.5 The reactions were run initially
at -20 °C for 3 h to examine the effects of the catalysts on
the â/R ratio as well as the total conversion to the R- and
â-anomers. The reaction was assayed by using reversed-
phase (C18 column) HPLC. The results are summarized in
Table 1.
Table 1 indicates that the best overall catalyst was stannic
chloride for coupling of 1 with the silylated 5-iodopyrimi-
dinone 2 to produce the â-anomer of IPdR (3). Good â/R
ratios and excellent conversions were achieved using stannic
chloride as the catalyst. TLC and HPLC assays indicate the
near disappearance of starting materials.
While monitoring the coupling reaction with TLC using
p-nitrophenol as the catalyst, it was observed that after 30
min of the reaction, the major product formed was the
â-anomer, and only a trace amount of the R-anomer was
detected. As the reaction continued, more R-anomer was
produced. At the end of 3 h, the â/R ratio was 1.5/1si.e.,
60% â-anomer and 40% R-anomer. There was still a
significant amount (60%) of unreacted protected sugar
chloride remaining. However, it was obvious from this
experiment that formation of the â-anomer was kinetically
controlled, while the formation of R-anomer was thermo-
dynamically controlled. This strongly suggests that the
product distribution of these coupling reactions is dependent
on thermodynamic and kinetic factors. Therefore, to under-
Introduction
Current interest in synthesizing drugs active against
antiviral1-3 and antitumor4,5 agents have concentrated on the
synthesis of â-nucleosides. Since most ribonuclesides and
2-deoxyribonucleosides exist as a â-anomer in nature,
stereoselective synthesis of the â-nucleosides has become
an enormous challenge to all synthetic chemists. Increasingly,
more drugs are nucleoside based, such as the dideoxynucleo-
side derivatives (e.g., AZT, ddC, ddl, 3TC) used in the
treatment of AIDS.6
The most common nucleosides consist of pyrimidine bases
coupled to a 2-deoxyribose sugar at the 1′ position. The
pyrimidine bases coupled to cytosine and uracil derivatives
have shown the most consistent activity against the virus.7,8
As uracil compounds cannot be deaminated in vivo, there is
a strong interest in their selectivity as well as their ability to
form stable derivatives.9 A method frequently used in the
synthesis is the Vorbruggen coupling (Scheme 1).10 However,
(1) Weygand, F.; Wacker, A.; Dellwag, Z. Naturforsch, Teil B 1952, 7, 19.
(2) Belts, R. E.; Visser, D. J. Am. Chem. Soc. 1955, 77, 736.
(3) Belts, R. E.; Viser, D.; Frisch, D. M. Biochem. Pharmacol. 1960, 5, 157.
(4) Heidelberg, C.; Griesbach, L.; Cruz, O.; Schnitter, R. J.; Grunberg, E. Proc.
Soc. Exp. Biol. Med. 1958, 97, 470.
(5) Burchenal, J. H.; Holmberg, A. D.; Fox, J. J.; Hemphill, S. C.; Reppert, J.
A. Cancer Res. 1959, 19, 497.
(6) Mitsuya, H.; Weinhold, K. J.; Furman, P. A.; St. Clair, M. H.; Lehrman,
S. N.; Gallo, R. C.; Bolognesi, D.; Barry, D. W.; Broder, S. Proc. Natl.
Acad. Sci. U.S.A. 1985, 82, 7096.
(7) Prusoff, W. H.; Chen, M. S.; Fischer, P. H.; Lin, T. S. AdV. Ophthalmol.
1979, 38, 3.
(8) Cheng, Y. C.; Hoffman, P. J.; Ostrander, M. AdV. Ophthalmol. 1979, 38,
1976.
(9) Efange, S. M. N.; Alessi, E. M.; Shih, H. C.; Cheng, Y.; Bardos, T. J.
Med. Chem. 1985, 28, 904.
(10) (a) Niedballa, U.; Vorbruggen, H. J. Org. Chem. 1974, 39, 3654. (b)
Vorbruggen, H.; Bennua, B. Chem. Ber. 1981, 114, 1279.
(11) Lipshutz, B. H.; Hayakawa, H.; Kato, K.; Lowe, R. F.; Stevens, K. L.
Synthesis 1994, 1476.
(12) Okasuchi, T.; Kubota, H.; Narasaka, K. Chem. Lett. 1989, 801.
10.1021/op980204o CCC: $18.00 © 1999 American Chemical Society and Royal Society of Chemistry
Published on Web 01/08/1999
Vol. 3, No. 2, 1999 / Organic Process Research & Development
•
135